compound 065

Compound 065 is a synthetic chalcone derivative developed as a potential antineoplastic agent for the treatment of ovarian cancer. It was identified through three-dimensional quantitative structure-activity relationship (3D-QSAR) modeling, specifically using Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Index Analysis (CoMSIA), to optimize antiproliferative activity against the A2780 ovarian cancer cell line. Compound 065 exerts its cytotoxic effects via a reactive oxygen species (ROS)-dependent mechanism, which includes the upregulation of heme oxygenase-1 (HO-1) and the induction of oxidative stress. Notably, its activity is maintained in cisplatin-resistant cell models, and its mechanism appears to be independent of the canonical Nrf2 antioxidant signaling pathway. The compound was developed by a multidisciplinary research team led by scientists at the Universidad Central de Chile.